Luminex (LMNX) Reaches $30.80 52-Week High; Finjan Holdings (FNJN) Shorts Up By 15.66%

June 20, 2018 - By Maria Brooks

Luminex Corporation (NASDAQ:LMNX) Logo

Finjan Holdings Inc (NASDAQ:FNJN) had an increase of 15.66% in short interest. FNJN’s SI was 641,200 shares in June as released by FINRA. Its up 15.66% from 554,400 shares previously. With 495,300 avg volume, 1 days are for Finjan Holdings Inc (NASDAQ:FNJN)’s short sellers to cover FNJN’s short positions. The SI to Finjan Holdings Inc’s float is 3.9%. The stock increased 7.55% or $0.225 during the last trading session, reaching $3.205. About 761,980 shares traded or 121.85% up from the average. Finjan Holdings, Inc. (NASDAQ:FNJN) has declined 13.57% since June 20, 2017 and is downtrending. It has underperformed by 26.14% the S&P500. Some Historical FNJN News: ; 27/03/2018 – Finjan Holdings to Host a Shareholder Update on April 5, 2018; 04/05/2018 – Finjan Files Patent Infringement Complaint Against Check Point USA and Check Point Israel; 19/03/2018 – FINJAN HOLDINGS- ON MARCH 19, UNIT OF CO RECEIVED $65 MLN PAYMENT DUE FROM SYMANTEC CORP UNDER CONFIDENTIAL PATENT LICENSE AND SETTLEMENT AGREEMENT; 09/04/2018 – FINJAN HOLDINGS INC – TERMS OF AGREEMENT BETWEEN CO, UNIT FINJAN & CARBON BLACK AND BETWEEN FINJAN MOBILE & CARBON BLACK ARE CONFIDENTIAL; 09/04/2018 – FINJAN HOLDINGS – FINJAN MOBILE & CARBON BLACK ENTERED INTO SEPARATE CONFIDENTIAL PATENT CROSS LICENSE AGREEMENT; 03/04/2018 – $FNJN $CSCO Finjan prevails against Cisco Systems as both ‘494 and ‘844 IPR patent challenge trials are denied; 04/05/2018 – FINJAN FILES PATENT COMPLAINT VS CHECK POINT ISRAEL; 10/05/2018 – Finjan Announces $10 Million Share Repurchase Program; 05/04/2018 – Finjan Holdings 1Q EPS $1.55; 22/03/2018 – FINJAN HOLDINGS INC SAYS ITS SUBSIDIARY FINJAN, INC HAS FILED A PATENT INFRINGEMENT LAWSUIT AGAINST CARBON BLACK

The stock of Luminex Corporation (NASDAQ:LMNX) hit a new 52-week high and has $32.03 target or 4.00% above today’s $30.80 share price. The 6 months bullish chart indicates low risk for the $1.37B company. The 1-year high was reported on Jun, 20 by If the $32.03 price target is reached, the company will be worth $54.76M more. The stock increased 1.22% or $0.37 during the last trading session, reaching $30.8. About 50,846 shares traded. Luminex Corporation (NASDAQ:LMNX) has risen 33.74% since June 20, 2017 and is uptrending. It has outperformed by 21.17% the S&P500. Some Historical LMNX News: ; 18/05/2018 – Luminex Declares Dividend of 6c; 07/05/2018 – LUMINEX 1Q ADJ EPS 25C, EST. 26C; 07/05/2018 – Luminex 1Q Adj EPS 25c; 02/05/2018 – ST Denis J Villere & Company Exits Position in Luminex; 07/05/2018 – LUMINEX CORP LMNX.O FY2018 REV VIEW $313.0 MLN — THOMSON REUTERS l/B/E/S; 07/05/2018 – Luminex Backs FY18 Rev $310M-$316M; 07/05/2018 – LUMINEX CORP LMNX.O SEES FY 2018 REVENUE $310 MLN TO $316 MLN; 07/05/2018 – Luminex 1Q Rev $82.7M; 07/05/2018 – Luminex 1Q EPS 30c; 20/04/2018 – DJ Luminex Corp, Inst Holders, 1Q 2018 (LMNX)

Finjan Holdings, Inc., through its subsidiaries, operates as a cybersecurity company, provides intellectual property licensing and enforcement services. The company has market cap of $88.88 million. The firm owns a portfolio of patents related to software and hardware technologies that proactively detect malicious code and thereby protects end users from identity and data theft, spyware, malware, phishing, trojans, and other Web and network threats. It has a 3 P/E ratio. The Company’s patented technologies are used in specific cybersecurity technology areas, including endpoint/cloud software, Web gateway/Internet infrastructure, networking equipment markets, and mobile security.

Among 2 analysts covering Finjan Holdings (NASDAQ:FNJN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Finjan Holdings had 3 analyst reports since May 20, 2016 according to SRatingsIntel. The rating was initiated by B. Riley & Co on Friday, May 20 with “Buy”. As per Tuesday, January 2, the company rating was maintained by FBR Capital.

More news for Luminex Corporation (NASDAQ:LMNX) were recently published by:, which released: “Detailed Research: Economic Perspectives on MGM Growth Properties, Acacia Research, Luminex, Eastman …” on June 20, 2018.‘s article titled: “Luminex Corp. (LMNX) Initiates Clinical Trials for VERIGENE II Gastrointestinal Assay” and published on June 13, 2018 is yet another important article.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The company has market cap of $1.37 billion. The company??s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It has a 40.47 P/E ratio. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

Analysts await Luminex Corporation (NASDAQ:LMNX) to report earnings on August, 6. They expect $0.20 EPS, 0.00% or $0.00 from last year’s $0.2 per share. LMNX’s profit will be $8.89M for 38.50 P/E if the $0.20 EPS becomes a reality. After $0.25 actual EPS reported by Luminex Corporation for the previous quarter, Wall Street now forecasts -20.00% negative EPS growth.

Luminex Corporation (NASDAQ:LMNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: